Avantax Planning Partners Inc. Has $11.85 Million Position in Merck & Co., Inc. $MRK

Avantax Planning Partners Inc. lowered its position in shares of Merck & Co., Inc. (NYSE:MRK) by 11.7% in the first quarter, Holdings Channel reports. The institutional investor owned 98,512 shares of the company’s stock after selling 13,075 shares during the period. Avantax Planning Partners Inc.’s holdings in Merck & Co., Inc. were worth $11,850,000 as of its most recent filing with the SEC.

Several other institutional investors have also made changes to their positions in MRK. Kingdom Financial Group LLC. bought a new stake in shares of Merck & Co., Inc. during the 4th quarter valued at $25,000. Abound Financial LLC acquired a new stake in shares of Merck & Co., Inc. in the 4th quarter valued at approximately $26,000. Prosperity Bancshares Inc acquired a new stake in Merck & Co., Inc. in the fourth quarter valued at approximately $26,000. High Note Wealth LLC boosted its holdings in shares of Merck & Co., Inc. by 58.9% during the 4th quarter. High Note Wealth LLC now owns 294 shares of the company’s stock valued at $31,000 after acquiring an additional 109 shares in the last quarter. Finally, IFC & Insurance Marketing Inc. acquired a new stake in shares of Merck & Co., Inc. during the fourth quarter valued at about $31,000. 76.07% of the stock is currently owned by institutional investors.

Key Stories Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: The FDA expanded approval for Merck’s Keytruda, in combination with Pfizer’s Padcev, for use in muscle-invasive bladder cancer regardless of cisplatin eligibility, potentially expanding the market opportunity for one of Merck’s most important cancer drugs. FDA Expands MRK & PFE’s Keytruda-Padcev Combo Use in Bladder Cancer
• Positive Sentiment: JPMorgan, BMO Capital Markets, and Guggenheim all raised their price targets on Merck and maintained bullish ratings, signaling improved Wall Street confidence in MRK’s upside. Analyst price target updates
• Positive Sentiment: Commentary highlighting Merck as a bargain and the stock’s recent attention in the S&P 500 focus list may be adding to investor optimism around the shares. Merck (MRK) Stock Looks Like A Bargain At This Price
• Neutral Sentiment: There was also discussion of Merck’s Januvia/Janumet franchise as a benchmark in a generic drug partnership story, but this appears to be more contextual than a direct new catalyst for MRK today. Cosmos Health Accelerates Prescription Medicine Strategy…
• Negative Sentiment: Retail chatter continues to focus on Merck’s looming Keytruda patent cliff, which remains a longer-term risk even as near-term news flow is positive. SLS Vs MLTX: Retail Traders Race To Pick Merck’s Next Biotech Buyout…

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the stock. Weiss Ratings cut shares of Merck & Co., Inc. from a “hold (c+)” rating to a “hold (c)” rating in a research note on Friday, May 15th. Wells Fargo & Company raised their price objective on shares of Merck & Co., Inc. from $145.00 to $150.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 8th. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $142.00 target price on shares of Merck & Co., Inc. in a research report on Wednesday, July 8th. BMO Capital Markets boosted their price target on shares of Merck & Co., Inc. from $135.00 to $142.00 and gave the company an “outperform” rating in a research note on Monday. Finally, Wall Street Zen raised Merck & Co., Inc. from a “hold” rating to a “buy” rating in a research note on Sunday. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and seven have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $133.94.

Merck & Co., Inc. Price Performance

Shares of NYSE:MRK opened at $123.93 on Tuesday. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.06 and a current ratio of 1.30. The company has a market capitalization of $306.09 billion, a P/E ratio of 34.91, a price-to-earnings-growth ratio of 2.65 and a beta of 0.19. Merck & Co., Inc. has a fifty-two week low of $76.66 and a fifty-two week high of $130.29. The company’s 50-day moving average is $119.12 and its 200 day moving average is $116.50.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.47) by $0.19. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The company had revenue of $16.29 billion during the quarter, compared to analyst estimates of $15.85 billion. During the same quarter last year, the business posted $2.22 EPS. Merck & Co., Inc.’s quarterly revenue was up 4.9% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. On average, equities research analysts forecast that Merck & Co., Inc. will post 5.17 earnings per share for the current year.

Merck & Co., Inc. Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, July 8th. Shareholders of record on Monday, June 15th were given a dividend of $0.85 per share. This represents a $3.40 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date was Monday, June 15th. Merck & Co., Inc.’s dividend payout ratio (DPR) is currently 95.77%.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.